Blue Ridge Mountain Resources, Inc. Announces Divestiture of Equity Interest in Eureka Midstream
Sep 28, 2017 21:00 pm UTC| Business
IRVING, Texas, Sept. 28, 2017 -- Blue Ridge Mountain Resources, Inc. (“BRMR”) announced today that it has entered into a definitive agreement to divest 100% of BRMR’s equity investment in Eureka Midstream Holdings, LLC...
Serinus Energy Announces Board Appointment
Sep 28, 2017 21:00 pm UTC| Business
CALGARY, Alberta, Sept. 28, 2017 -- Serinus Energy Inc. (“Serinus”, “SEN” or the “Company”) (TSX:SEN) (WARSAW:SEN) is pleased to announce the appointment of Mr. James (Jim) Causgrove as an independent member of the...
Nabriva Therapeutics to Present Lefamulin Data at ID Week 2017
Sep 28, 2017 20:58 pm UTC| Business
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 28, 2017 -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to...
SBA Announces Pricing of $750 Million of 4.0% Senior Notes Due 2022
Sep 28, 2017 20:58 pm UTC| Business
BOCA RATON, Fla., Sept. 28, 2017 -- SBA Communications Corporation (NASDAQ:SBAC) (“SBA”) announced today that it has priced an offering of $750 million aggregate principal amount of senior notes due 2022 (the “Notes”),...
ArcelorMittal announces US$1.0 billion three-year investment programme in Mexico
Sep 28, 2017 20:46 pm UTC| Business
28 September 2017 - ArcelorMittal ('the Company') today announces a major US$1 billion, three-year investment programme at its Mexican operations, which is focussed on building ArcelorMittal Mexico's downstream...
Sep 28, 2017 20:45 pm UTC| Business
SEATTLE, Sept. 28, 2017 -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, today announced that it has amended the terms of a...
Aptevo Therapeutics Completes Sale of Hyperimmune Products for Up to $74.5 Million
Sep 28, 2017 20:35 pm UTC| Business
Sharpens Focus on Innovative ADAPTIR® Bispecific Antibody Platform and IXINITY® Commercial Asset Strengthens Cash Position to Advance RD and Commercial Strategy SEATTLE, Sept. 28, 2017 -- Aptevo Therapeutics Inc....